Last week we discussed the array of therapeutic options in the pipeline for patients with MDS. Today we shine a spotlight on NAE inhibitors, the first of which recently received FDA breakthrough designation to bring it to the clinic faster. To answer our questions about the current data and future therapeutic use for this novel class of drugs, we welcome Dr Magnus Tobiasson, senior consultant in internal medicine and hematology at Karolinska University Hospital in Huddinge, Sweden.

References: 

• Swords, et al. Br J Haematol. 2015 (4):534-43
• Zhu, et al. Genes (Basel). 2020; 11(9): E990
• Majidi, et al. Blood. 2017; 130(1): 5298
• Ades, et al. ASCO 2020. Abstract 7506

This series is supported by educational grants from Servier Pharmaceuticals LLC and Takeda, who have had no influence on the content or choice of faculty.